Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Northera (droxidopa) is indicated for the treatment of orthostatic dizziness and light-headedness, or the "feeling that you are about to black out," in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Pharmacologic treatments, including droxidopa, were effective in reducing Postural Orthostatic Tachycardia Syndrome (POTS) symptoms and increasing orthostatic tolerance, although the studies had small sample sizes (10-50 subjects).
• Droxidopa, midodrine, and pyridostigmine were noted as effective in preventing Orthostatic Hypotension (OH), with clonidine and beta-blockers used to treat Supine Hypertension (SH) without causing significant hypotension.
• No significant differences in effectiveness among different population types or subgroups were reported in the studies.
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.